Table 6 Clinical outcomes by the selected studies Melanoma and Immunotherapy
From: Oligometastasis and local ablation in the era of systemic targeted and immunotherapy
Authors (year of publication) [reference] | Local Control | Progression free survival | Overall Survival | Toxicity |
|---|---|---|---|---|
Gabani 2018 [35] | N/A | N/A | 15.4 mo (median) | N.S. |
Stera 2018 [36] | 1 yr LCR: 89.5% | 6 mo: 42.3% 1 yr: 25.5% | 6 mo: 75.3% 1 yr: 50.8% 2 yr: 31.8% | 3 > G2 (1 autoimmune hypophysitis, 1 autoimmune pancreatitis, 1 radionecrosis)a |
Liniker 2016 [37] | RR: 44% e 64% b | 3 > G2 (1 case of radiation necrosis, 2 radiation dermatitis) | ||
Qin 2015 [32] | Ipi before RT > 6 and 12 mo response duration that Ipi after RT | 19.6 mo (median) 6 mo: 95.1% 1 yr: 79.7% | Pts. Who received Ipi after radiation had fewer irAEs than those who received it before radiation | |
Diao 2018 [33] | Non-concurrent Ipi: 1 yr, 70% Concurrent Ipi: 1 yr, 58% | N.S. | Non-concurrent Ipi: Median,18.7 mo 1 yr, 63% Concurrent Ipi Median, 11.8 mo 1 yr, 50% | Acute 4 > G2 (2 cases of cerebral oedema, 2 cases of cerebral hemorrhage)c Late 4 > G2 (Radiation Necrosis) No G5 events |
Anderson 2017 [34] | 93% (at the time of death) | N.S. | N.S. | No > G3 events 1 G2 CNS bleeding |
Chen 2017 [15] | Non concurrent ICI: 1 yr 79% Concurrent ICI: 1 yr 88% | N.S. | Concurrent ICI: 24.7 mo Non-Concurrent ICI: 14.5 mo | 3% G3 acute CNS No > G3 events |
Chandra 2015 [38] | N.S. | 28 mo (median) | N.S. |